Alkermes Moves Beyond Reformulations As It Preps Three New Compounds For Clinic
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Alkermes multi-year efforts to move up from its successful reformulations for partners takes a step forward as the biotech presents its expanding clinical pipeline to investors, highlighting early-stage compounds for multiple sclerosis, pain and cancer.